Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML). Vosaroxin is an anticancer quinolone derivative (AQD). The Company's other kinase inhibitor pipeline include TAK-580, SNS-062 and SNS-229. TAK-580 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors. SNS-062 is a non-covalently binding inhibitor of Bruton's tyrosine kinase (BTK). The Company has completed the pre-clinical studies for SNS-062. SNS-229 and SNS-510 are two PDK1 inhibitors. PDK1 is a kinase and mediator of Phosphoinositide 3-kinase/AKT (PI3K/AKT) signaling, which is a pathway involved in cell growth, differentiation, survival and migration.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research - NEC
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:SNSS
- CUSIP: 86732860
- Web: www.sunesis.com
Capitalization:- Market Cap: $55.07 million
- Outstanding Shares: 21,460,000
Average Prices:- 50 Day Moving Avg: $2.83
- 200 Day Moving Avg: $3.58
- 52 Week Range: $2.50 - $6.30
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.21
- P/E Growth: -0.01
Sales & Book Value:- Annual Revenue: $2.57 million
- Price / Sales: 21.38
- Book Value: ($0.21) per share
- Price / Book: -12.19
Profitability:- EBIDTA: ($36,020,000.00)
- Net Margins: -1,472.94%
- Return on Assets: -109.38%
Debt:- Current Ratio: 3.15%
- Quick Ratio: 3.15%
Misc:- Average Volume: 129,130 shs.
- Beta: 1.77
- Short Ratio: 1.74
Frequently Asked Questions for Sunesis Pharmaceuticals (NASDAQ:SNSS)
What is Sunesis Pharmaceuticals' stock symbol?
Sunesis Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNSS."
How were Sunesis Pharmaceuticals' earnings last quarter?
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) posted its earnings results on Monday, May, 8th. The company reported ($0.47) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.83) by $0.36. The company had revenue of $0.67 million for the quarter, compared to analysts' expectations of $1.57 million. The business's revenue was up 4.7% on a year-over-year basis. During the same period in the previous year, the business posted ($0.12) earnings per share. View Sunesis Pharmaceuticals' Earnings History.
When will Sunesis Pharmaceuticals make its next earnings announcement?
Where is Sunesis Pharmaceuticals' stock going? Where will Sunesis Pharmaceuticals' stock price be in 2017?
3 equities research analysts have issued twelve-month price objectives for Sunesis Pharmaceuticals' stock. Their predictions range from $3.00 to $3.00. On average, they expect Sunesis Pharmaceuticals' share price to reach $3.00 in the next year. View Analyst Ratings for Sunesis Pharmaceuticals.
What are analysts saying about Sunesis Pharmaceuticals stock?
Here are some recent quotes from research analysts about Sunesis Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. It has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. It is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. " (7/11/2017)
- 2. Cantor Fitzgerald analysts commented, "Losing Vosaroxin. SNSS has withdrawn its MAA in the EU for vosaroxin, ending the company’s chances, we believe, for marketing approval without additional clinical studies." (5/2/2017)
Who are some of Sunesis Pharmaceuticals' key competitors?
Some companies that are related to Sunesis Pharmaceuticals include Vernalis plc (VER), CTI BioPharma Corp. (CTIC), Brainstorm Cell Therapeutics (BCLI), ArQule (ARQL), CytRx Corporation (CYTR), GTx (GTXI), Tissue Regenix Group PLC (TRX), Eiger BioPharmaceuticals (EIGR), aTyr Pharma (LIFE), Navidea Biopharmaceuticals (NAVB), Galectin Therapeutics (GALT), Silence Therapeutics plc (SLN), Abzena PLC (ABZA), Infinity Pharmaceuticals (INFI), Palatin Technologies (PTN), CASI Pharmaceuticals (CASI), NovaBay Pharmaceuticals (NBY) and NovaBay Pharmaceuticals (NBY).
Who are Sunesis Pharmaceuticals' key executives?
Sunesis Pharmaceuticals' management team includes the folowing people:
- Daniel N. Swisher Jr., President, Chief Executive Officer, Director
- Adam R. Craig M.D., Ph.D., Executive Vice President - Development, Chief Medical Officer
- James W. Young Ph.D., Non-Executive Independent Chairman of the Board
- Stephen B. Ketchum Ph.D., Director
- Geoffrey M. Parker, Director
- Steve R Carchedi, Independent Director
- Matthew K. Fust, Independent Director
Who owns Sunesis Pharmaceuticals stock?
Sunesis Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include
BALYASNY ASSET MANAGEMENT LLC
(9.32%). Company insiders that own Sunesis Pharmaceuticals stock include Daniel N Swisher Jr, Dayton Misfeldt and Geoffrey M Parker. View Institutional Ownership Trends for Sunesis Pharmaceuticals.
How do I buy Sunesis Pharmaceuticals stock?
Shares of Sunesis Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sunesis Pharmaceuticals' stock price today?
One share of Sunesis Pharmaceuticals stock can currently be purchased for approximately $2.56.
MarketBeat Community Rating for Sunesis Pharmaceuticals (NASDAQ SNSS)MarketBeat's community ratings are surveys of what our community members think about Sunesis Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Sunesis Pharmaceuticals (NASDAQ:SNSS) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Hold Ratings, 1 Buy Rating |
| Consensus Rating: | Hold (Score: 2.33) |
| Consensus Price Target: | $3.00 (17.19% upside) |
Analysts' Ratings History for Sunesis Pharmaceuticals (NASDAQ:SNSS)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 5/2/2017 | Cantor Fitzgerald | Reiterated Rating | Hold | $3.00 | High |  |
| 11/3/2016 | Cowen and Company | Reiterated Rating | Hold | | N/A | |
| 7/29/2016 | Wells Fargo & Company | Upgrade | Market Perform -> Outperform | | N/A | |
| 7/24/2015 | Roth Capital | Downgrade | Buy -> Sell | $5.50 -> $1.00 | N/A | |
(Data available from 7/23/2015 forward)
Earnings History for Sunesis Pharmaceuticals (NASDAQ:SNSS)Earnings History by Quarter for Sunesis Pharmaceuticals (NASDAQ SNSS)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 7/27/2017 | | ($0.59) | | | | | N/A | |
| 5/8/2017 | Q1 2017 | ($0.83) | ($0.47) | $1.57 million | $0.67 million | View | Listen | |
| 3/9/2017 | Q4 2016 | ($0.43) | ($0.44) | $0.60 million | $0.68 million | View | Listen | |
| 11/3/2016 | Q316 | ($0.71) | ($0.62) | $0.60 million | $0.60 million | View | N/A | |
| 7/29/2016 | Q216 | ($0.10) | ($0.12) | $0.70 million | $0.60 million | View | Listen | |
| 5/5/2016 | Q116 | ($0.12) | ($0.12) | $0.77 million | $0.64 million | View | Listen | |
| 3/10/2016 | Q415 | ($0.14) | ($0.15) | $0.84 million | $0.67 million | View | Listen | |
| 11/5/2015 | Q315 | ($0.12) | ($0.09) | $1.09 million | $0.68 million | View | Listen | |
| 7/30/2015 | Q215 | ($0.13) | ($0.15) | $1.21 million | $0.85 million | View | N/A | |
| 5/5/2015 | Q115 | ($0.16) | ($0.13) | $1.14 million | $0.90 million | View | Listen | |
| 3/12/2015 | Q414 | ($0.20) | ($0.02) | $1.17 million | $0.90 million | View | Listen | |
| 11/10/2014 | Q314 | ($0.17) | ($0.25) | $1.97 million | $0.85 million | View | Listen | |
| 8/5/2014 | Q214 | ($0.17) | ($0.20) | $1.32 million | $2.00 million | View | Listen | |
| 5/7/2014 | Q114 | ($0.17) | ($0.26) | $1.32 million | $2.00 million | View | Listen | |
| 3/6/2014 | Q413 | ($0.20) | ($0.15) | $1.37 million | $2.00 million | View | Listen | |
| 11/12/2013 | Q313 | ($0.20) | ($0.16) | $1.44 million | $1.99 million | View | Listen | |
| 7/29/2013 | Q2 2013 | ($0.21) | $0.18 | $1.22 million | $1.99 million | View | Listen | |
| 5/9/2013 | Q1 2013 | ($0.20) | ($0.23) | $0.75 million | $1.99 million | View | Listen | |
| 3/13/2013 | Q4 2012 | ($0.19) | ($0.20) | $0.32 million | $1.99 million | View | Listen | |
| 11/8/2012 | Q312 | ($0.11) | ($0.37) | $4.17 million | $0.26 million | View | N/A | |
| 8/9/2012 | | ($0.20) | ($0.20) | | | View | N/A | |
| 5/15/2012 | | ($0.18) | ($0.30) | | | View | N/A | |
| 11/14/2011 | | ($0.18) | ($0.11) | | | View | N/A | |
| 8/11/2011 | | ($0.15) | ($0.18) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Sunesis Pharmaceuticals (NASDAQ:SNSS)Current Year EPS Consensus Estimate: $-2.4 EPS
Next Year EPS Consensus Estimate: $-2.11 EPS
Dividend History for Sunesis Pharmaceuticals (NASDAQ:SNSS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Sunesis Pharmaceuticals (NASDAQ:SNSS)Insider Ownership Percentage: 10.21%
Institutional Ownership Percentage: 55.19%
Insider Trades by Quarter for Sunesis Pharmaceuticals (NASDAQ:SNSS)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 12/9/2016 | Geoffrey M Parker | Director | Buy | 3,740 | $3.87 | $14,473.80 | |
| 5/26/2016 | Geoffrey M Parker | Director | Buy | 9,500 | $0.47 | $4,465.00 | |
| 5/25/2016 | Geoffrey M Parker | Director | Buy | 52,505 | $0.47 | $24,677.35 | |
| 12/21/2015 | Dayton Misfeldt | Director | Buy | 1,750,000 | $0.84 | $1,470,000.00 | |
| 8/25/2015 | Daniel N Swisher Jr | CEO | Buy | 12,216 | $1.01 | $12,338.16 | |
| 8/24/2015 | Daniel N Swisher Jr | CEO | Buy | 12,784 | $1.01 | $12,911.84 | |
| 8/29/2014 | Forest Baskett | Major Shareholder | Sell | 266,700 | $7.97 | $2,125,599.00 | |
| 8/28/2014 | Bay City Capital Llc | Major Shareholder | Sell | 300,700 | $7.98 | $2,399,586.00 | |
| 8/28/2014 | Dayton Misfeldt | Director | Sell | 200,000 | $7.89 | $1,578,000.00 | |
| 8/27/2014 | Adam R Craig | CMO | Sell | 2,554 | $8.00 | $20,432.00 | |
| 8/27/2014 | Daniel N Swisher Jr | CEO | Sell | 5,000 | $8.00 | $40,000.00 | |
| 8/27/2014 | Dayton Misfeldt | Director | Sell | 100,700 | $8.16 | $821,712.00 | |
| 8/27/2014 | Eric Bjerkholt | CFO | Sell | 10,000 | $8.00 | $80,000.00 | |
| 8/27/2014 | Krishna Kittu Kolluri | Major Shareholder | Sell | 108,300 | $8.17 | $884,811.00 | |
| 8/12/2014 | Dayton Misfeldt | Director | Sell | 743,700 | $6.64 | $4,938,168.00 | |
| 8/12/2014 | Equity Opportunities Fu Growth | Major Shareholder | Sell | 710,540 | $6.63 | $4,710,880.20 | |
(Data available from 1/1/2013 forward)
Headline Trends for Sunesis Pharmaceuticals (NASDAQ:SNSS)
Latest Headlines for Sunesis Pharmaceuticals (NASDAQ:SNSS)
| Source: |
|
| Date | Headline |
|---|
 | Sunesis Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 Study Evaluating Oral Non-Covalent BTK ... - GlobeNewswire (press release)
globenewswire.com - July 20 at 7:56 AM |
 | Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - July 20 at 7:42 AM |
 | Sunesis Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 Study Evaluating Oral Non-Covalent BTK-inhibitor SNS-062 in Adults with Chronic Lymphocytic Leukemia and other B-Cell Malignancies
finance.yahoo.com - July 18 at 8:48 PM |
| Sunesis Pharmaceuticals (SNSS) vs. Biohaven Pharmaceutical Holding Co (BHVN) Critical Analysis
www.americanbankingnews.com - July 17 at 9:55 AM |
| -$0.76 EPS Expected for Sunesis Pharmaceuticals, Inc. (SNSS) This Quarter
www.americanbankingnews.com - July 6 at 7:36 AM |
| Sunesis Pharmaceuticals, Inc. (SNSS) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - June 28 at 7:30 AM |
| Sunesis Pharmaceuticals Added to Russell Microcap® Index - GlobeNewswire (press release)
globenewswire.com - June 27 at 8:01 PM |
| Sunesis Pharmaceuticals Added to Russell Microcap® Index
finance.yahoo.com - June 27 at 8:30 AM |
 | Sunesis Pharmaceuticals (SNSS) Announces Presentation of ... - StreetInsider.com
www.streetinsider.com - June 24 at 6:51 AM |
| Sunesis Pharmaceuticals Announces Presentation of Updated Results from Washington University-Sponsored Phase 1/Cohort Expansion Trial of Vosaroxin Plus Azacitidine in Patients with MDS at the EHA Annual Meeting
finance.yahoo.com - June 24 at 6:51 AM |
| Analysts Expect Sunesis Pharmaceuticals, Inc. (SNSS) to Post -$0.76 EPS
www.americanbankingnews.com - June 12 at 8:30 AM |
| IMPORTANT INVESTOR ALERT: Lundin Law PC Announces an Investigation of Sunesis Pharmaceuticals, Inc. and Advises Investors with Losses to Contact the Firm
finance.yahoo.com - May 20 at 5:35 AM |
| The Life Sciences Report Examines How Sunesis Pharmaceuticals Shifts Focus to Leukemia Drug
finance.yahoo.com - May 19 at 10:01 AM |
| -$0.76 Earnings Per Share Expected for Sunesis Pharmaceuticals, Inc. (SNSS) This Quarter
www.americanbankingnews.com - May 15 at 8:16 PM |
| Zacks Investment Research Upgrades Sunesis Pharmaceuticals, Inc. (SNSS) to Buy
www.americanbankingnews.com - May 13 at 11:16 PM |
| Edited Transcript of SNSS earnings conference call or presentation 8-May-17 6:00pm GMT
finance.yahoo.com - May 13 at 12:44 AM |
| Brokers Set Expectations for Sunesis Pharmaceuticals, Inc.'s FY2017 Earnings (SNSS)
www.americanbankingnews.com - May 12 at 12:32 PM |
| ETFs with exposure to Sunesis Pharmaceuticals, Inc. : May 11, 2017
finance.yahoo.com - May 11 at 9:01 PM |
| Sunesis Pharmaceuticals, Inc. :SNSS-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017
finance.yahoo.com - May 10 at 10:44 AM |
| Sunesis Pharmaceuticals Reports First Quarter 2017 Financial Results and Recent Highlights - GlobeNewswire (press release)
globenewswire.com - May 9 at 7:25 PM |
| Sunesis Pharmaceuticals, Inc. (SNSS) Releases Quarterly Earnings Results, Beats Expectations By $0.22 EPS
www.americanbankingnews.com - May 8 at 3:18 PM |
| Sunesis Pharmaceuticals Reports First Quarter 2017 Financial Results and Recent Highlights
finance.yahoo.com - May 8 at 11:13 AM |
| Investor Network: Sunesis Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - May 8 at 11:13 AM |
 | Sunesis reports 1Q loss
marketbeat.com - May 8 at 7:06 AM |
| IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Sunesis Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - May 4 at 8:16 PM |
 | INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Sunesis Pharmaceuticals, Inc. Investors
www.businesswire.com - May 3 at 11:07 PM |
| INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Sunesis Pharmaceuticals, Inc. Investors
finance.yahoo.com - May 3 at 11:07 PM |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Sunesis Pharmaceuticals Inc.
finance.yahoo.com - May 3 at 6:05 PM |
| IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Sunesis Pharmaceuticals, Inc. and Advises Investors with Losses to Contact the Firm
finance.yahoo.com - May 3 at 6:05 PM |
 | Sunesis Pharmaceuticals Announces Withdrawal of European Marketing Authorization Application (MAA)
www.nasdaq.com - May 3 at 10:45 AM |
| SUNESIS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Sunesis Pharmaceuticals Inc. To Contact The Firm
finance.yahoo.com - May 3 at 10:45 AM |
| SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Sunesis Pharmaceuticals, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
finance.yahoo.com - May 3 at 10:45 AM |
| INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Sunesis Pharmaceuticals, Inc.
finance.yahoo.com - May 3 at 10:45 AM |
| Sunesis Pharmaceuticals (SNSS) Earns Media Sentiment Score of -0.05
www.americanbankingnews.com - May 2 at 6:12 PM |
| SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Sunesis Pharmaceuticals, Inc. (SNSS)
finance.yahoo.com - May 2 at 5:46 PM |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sunesis Pharmaceuticals, Inc. - SNSS
finance.yahoo.com - May 2 at 5:46 PM |
| BUZZ-U.S. STOCKS ON THE MOVE-Angie's List, Tenet, Chegg, AMD, Coach, Merck, Sunesis Pharma - Nasdaq
www.nasdaq.com - May 2 at 9:21 AM |
| AZN Gets FDA Nod, CORT Boosts Outlook Yet Again, SNSS Withdraws Vosaroxin MAA - Nasdaq
www.nasdaq.com - May 2 at 9:21 AM |
| Sunesis Pharmaceuticals Announces Withdrawal of European Marketing Authorization Application (MAA) for Vosaroxin ... - Yahoo Finance
finance.yahoo.com - May 2 at 9:21 AM |
| Sunesis Pharmaceuticals Inc. (SNSS) PT Lowered to $3 at Cantor Fitzgerald Following MAA Withdrawl - StreetInsider.com
www.streetinsider.com - May 2 at 9:21 AM |
| Sunesis Pharmaceuticals, Inc. (SNSS) Stock Rating Reaffirmed by Cantor Fitzgerald
www.americanbankingnews.com - May 2 at 8:46 AM |
| Sunesis Pharmaceuticals, Inc. (SNSS) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - May 1 at 7:42 PM |
| Sunesis Pharmaceuticals Announces Withdrawal of European Marketing Authorization Application (MAA) for Vosaroxin as a Treatment for Relapsed/Refractory AML
finance.yahoo.com - May 1 at 7:08 PM |
| Sunesis shares drop as biotech drops leukemia drug marketing application
finance.yahoo.com - May 1 at 7:08 PM |
| Sunesis Pharmaceuticals (SNSS) Getting Favorable Media Coverage, Analysis Finds
www.americanbankingnews.com - April 29 at 7:59 PM |
| Zacks: Analysts Anticipate Sunesis Pharmaceuticals, Inc. (SNSS) to Announce -$0.83 EPS
www.americanbankingnews.com - April 25 at 11:33 AM |
| Somewhat Favorable Media Coverage Very Likely to Affect Sunesis Pharmaceuticals (SNSS) Share Price
www.americanbankingnews.com - April 23 at 9:17 PM |
| Sunesis Pharmaceuticals (SNSS) Receiving Somewhat Critical Media Coverage, Study Finds
www.americanbankingnews.com - April 17 at 6:35 PM |
| Sunesis Pharmaceuticals, Inc. (SNSS) Short Interest Down 4.9% in March
www.americanbankingnews.com - April 16 at 12:20 PM |
| Sunesis Pharmaceuticals (SNSS) Getting Positive News Coverage, Report Shows
www.americanbankingnews.com - April 14 at 9:53 PM |
Sunesis Pharmaceuticals (SNSS) Chart for Sunday, July, 23, 2017
